Transgene’s updated analyst narrative keeps the fair value price target anchored at €1.10, indicating that the headline valuation marker is unchanged in the latest refresh. Bullish and bearish analysts alike are now focusing less on the level of the €1.10 target and more on how sensitive it is to shifts in the underlying assumptions that support it. As you read on, you will see what is driving these differing views and how to track the story as new information emerges. Stay updated as the...

Transgene SA (STU:TGNA) strengthens its financial position and showcases promising clinical advancements, setting the stage for future growth.

Transgene SA (FRA:TGNA) extends its financial runway and advances its individualized cancer vaccine programs amidst a challenging biotech environment.